| Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis KM Sjoquist, BH Burmeister, BM Smithers, JR Zalcberg, RJ Simes, ... The lancet oncology 12 (7), 681-692, 2011 | 1961 | 2011 |
| Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo-controlled phase II trial N Pavlakis, KM Sjoquist, AJ Martin, E Tsobanis, S Yip, YK Kang, YJ Bang, ... Journal of Clinical Oncology 34 (23), 2728-2735, 2016 | 242 | 2016 |
| Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial LA Chantrill, AM Nagrial, C Watson, AL Johns, M Martyn-Smith, ... Clinical cancer research 21 (9), 2029-2037, 2015 | 238 | 2015 |
| Chemotherapy and radiotherapy for advanced pancreatic cancer V Chin, A Nagrial, K Sjoquist, CA O'Connor, L Chantrill, AV Biankin, ... Cochrane Database of Systematic Reviews, 2018 | 166 | 2018 |
| Australasian Gastro-Intestinal Trials Group: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis KM Sjoquist, BH Burmeister, BM Smithers, JR Zalcberg, RJ Simes, ... Lancet Oncol 12 (7), 681-692, 2011 | 157 | 2011 |
| Personalizing survival predictions in advanced colorectal cancer: the ARCAD nomogram project KM Sjoquist, LA Renfro, RJ Simes, NC Tebbutt, S Clarke, MT Seymour, ... JNCI: Journal of the National Cancer Institute 110 (6), 638-648, 2018 | 109 | 2018 |
| PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors M Tang, RL O'Connell, F Amant, P Beale, O McNally, KM Sjoquist, P Grant, ... Gynecologic Oncology 154 (3), 531-538, 2019 | 78 | 2019 |
| Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials AM Nagrial, VT Chin, KM Sjoquist, M Pajic, LG Horvath, AV Biankin, D Yip Critical reviews in oncology/hematology 96 (3), 483-497, 2015 | 62 | 2015 |
| Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial–ANZGOG 0903 L Mileshkin, R Edmondson, RL O'Connell, KM Sjoquist, J Andrews, ... Gynecologic Oncology 154 (1), 29-37, 2019 | 55 | 2019 |
| Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial NC Tebbutt, TJ Price, DA Ferraro, N Wong, AS Veillard, M Hall, ... British journal of cancer 114 (5), 505-509, 2016 | 50 | 2016 |
| Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal‐seeking studies of targeted therapies for rare and neglected cancers S Thavaneswaran, L Sebastian, M Ballinger, M Best, D Hess, CK Lee, ... Medical Journal of Australia 209 (8), 354-355, 2018 | 49 | 2018 |
| Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study V Grünwald, D Chirovsky, WY Cheung, F Bertolini, MJ Ahn, MH Yang, ... Oral oncology 102, 104526, 2020 | 48 | 2020 |
| INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian … N Pavlakis, KM Sjoquist, E Tsobanis, A Martin, YK Kang, YJ Bang, ... Journal of Clinical Oncology 33 (3_suppl), 9-9, 2015 | 47 | 2015 |
| The role of hormonal therapy in gynecological cancers-current status and future directions KM Sjoquist, J Martyn, RJ Edmondson, ML Friedlander International Journal of Gynecologic Cancer 21 (7), 2011 | 45 | 2011 |
| Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum‐resistant/refractory recurrent ovarian cancer: the Gynecologic Cancer Intergroup … KM Sjoquist, ML Friedlander, RL O'Connell, M Voysey, MT King, ... The oncologist 18 (11), 1221-1228, 2013 | 43 | 2013 |
| Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check ML Friedlander, M Stockler, R O’Connell, M Voysey, A Oza, K Gillies, ... International Journal of Gynecologic Cancer 24 (5), 2014 | 42 | 2014 |
| Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic … MT King, MR Stockler, P Butow, R O’Connell, M Voysey, AM Oza, K Gillies, ... International Journal of Gynecologic Cancer 24 (5), 2014 | 38 | 2014 |
| Advances in molecular pathology and treatment of periampullary cancers MD Chandrasegaram, JW Chen, TJ Price, J Zalcberg, K Sjoquist, ... Pancreas 45 (1), 32-39, 2016 | 36 | 2016 |
| Personalising pancreas cancer treatment: when tissue is the issue KM Sjoquist, VT Chin, LA Chantrill, C O’Connor, C Hemmings, DK Chang, ... World journal of gastroenterology: WJG 20 (24), 7849, 2014 | 32 | 2014 |
| Challenges of international oncology trial collaboration—a call to action M Tang, H Joensuu, RJ Simes, TJ Price, S Yip, W Hague, KM Sjoquist, ... British Journal of Cancer 121 (7), 515-521, 2019 | 31 | 2019 |
